Literature DB >> 21310852

Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.

Jie Xu1, Yue Zhang, Philip A Berry, Jing Jiang, Peter E Lobie, John F Langenheim, Wen Y Chen, Stuart J Frank.   

Abstract

GH receptor (GHR) and prolactin (PRL) receptor (PRLR) are structurally similar cytokine receptor superfamily members that are highly conserved among species. GH has growth-promoting and metabolic effects in various tissues in vertebrates, including humans. PRL is essential for regulation of lactation in mammals. Recent studies indicate that breast tissue bears GHR and PRLR and that both GH and PRL may impact development or behavior of breast cancer cells. An important facet of human GH (hGH) and human PRL (hPRL) biology is that although hPRL interacts only with hPRLR, hGH binds well to both hGHR and hPRLR. Presently, we investigated potential signaling effects of both hormones in the estrogen receptor- and progesterone receptor-positive human T47D breast cancer cell line. We found that this cell type expresses ample GHR and PRLR and responds well to both hGH and hPRL, as evidenced by activation of the Janus kinase 2/signal transducer and activator of transcription 5 pathway. Immunoprecipitation studies revealed specific GHR-PRLR association in these cells that was acutely enhanced by GH treatment. Although GH caused formation of disulfide-linked and chemically cross-linked GHR dimers in T47D cells, GH preferentially induced tyrosine phosphorylation of PRLR rather than GHR. Notably, both a GHR-specific ligand antagonist (B2036) and a GHR-specific antagonist monoclonal antibody (anti-GHR(ext-mAb)) failed to inhibit GH-induced signal transducer and activator of transcription 5 activation. In contrast, although the non-GHR-specific GH antagonist (G120R) and the PRL antagonist (G129R) individually only partially inhibited GH-induced activation, combined treatment with these two antagonists conferred greater inhibition than either alone. These data indicate that endogenous GHR and PRLR associate (possibly as a GHR-PRLR heterodimer) in human breast cancer cells and that GH signaling in these cells is largely mediated by the PRLR in the context of both PRLR-PRLR homodimers and GHR-PRLR heterodimers, broadening our understanding of how these related hormones and their related receptors may function in physiology and pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21310852      PMCID: PMC3063080          DOI: 10.1210/me.2010-0255

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  60 in total

1.  Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.

Authors:  Richard J Brown; Julian J Adams; Rebecca A Pelekanos; Yu Wan; William J McKinstry; Kathryn Palethorpe; Ruth M Seeber; Thea A Monks; Karin A Eidne; Michael W Parker; Michael J Waters
Journal:  Nat Struct Mol Biol       Date:  2005-08-21       Impact factor: 15.369

Review 2.  Development and potential clinical uses of human prolactin receptor antagonists.

Authors:  Vincent Goffin; Sophie Bernichtein; Philippe Touraine; Paul A Kelly
Journal:  Endocr Rev       Date:  2005-04-06       Impact factor: 19.871

3.  Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse.

Authors:  Zhuohua Wang; Gail S Prins; Karen T Coschigano; John J Kopchick; Jeffrey E Green; Vera H Ray; Samad Hedayat; Konstantin T Christov; Terry G Unterman; Steven M Swanson
Journal:  Endocrinology       Date:  2005-09-01       Impact factor: 4.736

Review 4.  Should prolactin be reconsidered as a therapeutic target in human breast cancer?

Authors:  V Goffin; P Touraine; C Pichard; S Bernichtein; P A Kelly
Journal:  Mol Cell Endocrinol       Date:  1999-05-25       Impact factor: 4.102

5.  Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications.

Authors:  Samantha L Gadd; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2006-07-13

Review 6.  Prolactin involvement in breast cancer.

Authors:  B K Vonderhaar
Journal:  Endocr Relat Cancer       Date:  1999-09       Impact factor: 5.678

7.  A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis.

Authors:  Jing Jiang; Xiangdong Wang; Kai He; Xin Li; Changmin Chen; Peter P Sayeski; Michael J Waters; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2004-09-02

8.  Janus kinase 2 influences growth hormone receptor metalloproteolysis.

Authors:  Kimberly Loesch; Luqin Deng; Jon W Cowan; Xiangdong Wang; Kai He; Jing Jiang; Roy A Black; Stuart J Frank
Journal:  Endocrinology       Date:  2006-02-23       Impact factor: 4.736

9.  Treatment of IM-9 cells with human growth hormone (GH) promotes rapid disulfide linkage of the GH receptor.

Authors:  S J Frank; G Gilliland; C Van Epps
Journal:  Endocrinology       Date:  1994-07       Impact factor: 4.736

10.  Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization.

Authors:  Aamer M Qazi; Chon-Hwa Tsai-Morris; Maria L Dufau
Journal:  Mol Endocrinol       Date:  2006-03-23
View more
  25 in total

1.  Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.

Authors:  Weijie Zhang; Pengxu Qian; Xiao Zhang; Min Zhang; Hong Wang; Mingming Wu; Xiangjun Kong; Sheng Tan; Keshuo Ding; Jo K Perry; Zhengsheng Wu; Yuan Cao; Peter E Lobie; Tao Zhu
Journal:  J Biol Chem       Date:  2015-04-14       Impact factor: 5.157

2.  Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).

Authors:  Yue Zhang; Sajina Gc; Sweta B Patel; Ying Liu; Andrew J Paterson; John C Kappes; Jing Jiang; Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2019-05-14       Impact factor: 4.102

3.  Lactogens and estrogens in breast cancer chemoresistance.

Authors:  Gila Idelman; Eric M Jacobson; Traci R Tuttle; Nira Ben-Jonathan
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

4.  Genome-wide pathway analysis of breast cancer.

Authors:  Young Ho Lee; Jae-Hoon Kim; Gwan Gyu Song
Journal:  Tumour Biol       Date:  2014-05-08

Review 5.  STAT signaling in mammary gland differentiation, cell survival and tumorigenesis.

Authors:  S Haricharan; Y Li
Journal:  Mol Cell Endocrinol       Date:  2013-03-28       Impact factor: 4.102

6.  Growth hormone-induced JAK2 signaling and GH receptor down-regulation: role of GH receptor intracellular domain tyrosine residues.

Authors:  Luqin Deng; Jing Jiang; Stuart J Frank
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

7.  Hormonal regulation of epithelial organization in a three-dimensional breast tissue culture model.

Authors:  Lucia Speroni; Gregory S Whitt; Joanna Xylas; Kyle P Quinn; Adeline Jondeau-Cabaton; Clifford Barnes; Irene Georgakoudi; Carlos Sonnenschein; Ana M Soto
Journal:  Tissue Eng Part C Methods       Date:  2013-06-25       Impact factor: 3.056

8.  Human GH receptor-IGF-1 receptor interaction: implications for GH signaling.

Authors:  Yujun Gan; Ashiya Buckels; Ying Liu; Yue Zhang; Andrew J Paterson; Jing Jiang; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2014-09-11

9.  IGF-1R modulation of acute GH-induced STAT5 signaling: role of protein tyrosine phosphatase activity.

Authors:  Yujun Gan; Yue Zhang; Ashiya Buckels; Andrew J Paterson; Jing Jiang; Thomas L Clemens; Zhong-Yin Zhang; Keyong Du; Yingzi Chang; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2013-09-12

10.  Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.

Authors:  Ying Liu; Jing Jiang; Bradford Lepik; Yue Zhang; Kurt R Zinn; Stuart J Frank
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.